Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.78+0.01 (+0.36%)
Close on Nov 17, 2026Market cap $23.19MP/E –Yield –
Evaxion A/S r&d expenses
Research and development expenses are spending on new products and technology.
Evaxion A/S's R&D Expenses for the twelve months ending Jun 30, 2022 was $19.49M, up 31.4% year over year. For fiscal 2025 it was $9.98M, down 4.6% from the year before. The highest annual figure on record is $19.58M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.98M | -4.6% |
| FY2024 | Dec 31, 2024 | $10.46M | -12.2% |
| FY2023 | Dec 31, 2023 | $11.92M | -30.1% |
| FY2022 | Dec 31, 2022 | $17.06M | -12.9% |
| FY2021 | Dec 31, 2021 | $19.58M | +79.6% |
| FY2020 | Dec 31, 2020 | $10.90M | +32.7% |
| FY2019 | Dec 31, 2019 | $8.22M | +120.3% |
| FY2018 | Dec 31, 2018 | $3.73M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.33M | -43.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.17M | -54.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.75M | -55.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.94M | -33.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.11M | -19.5% |
| Q1 FY2022 | Mar 31, 2022 | $4.80M | +23.4% |
| Q4 FY2021 | Dec 31, 2021 | $6.15M | +115.5% |
| Q3 FY2021 | Sep 30, 2021 | $4.42M | +48.9% |
| Q2 FY2021 | Jun 30, 2021 | $5.11M | +98.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.89M | +55.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.86M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.97M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.57M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.51M | – |
See a number that looks wrong?